Seutic Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 22-12-2024
- Paid Up Capital ₹ 1.50 Cr
as on 22-12-2024
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 58.20 Cr
as on 22-12-2024
- Satisfied Charges ₹ 4.00 M
as on 22-12-2024
- Revenue 83.76%
(FY 2022)
- Profit 133.89%
(FY 2022)
- Ebitda 34.77%
(FY 2022)
- Net Worth 24.73%
(FY 2022)
- Total Assets 57.63%
(FY 2022)
About Seutic Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.50 Cr.
The company currently has active open charges totaling ₹58.20 Cr. The company has closed loans amounting to ₹4.00 M, as per Ministry of Corporate Affairs (MCA) records.
Venkata Valivarthi and Padma Valivarthi serve as directors at the Company.
- CIN/LLPIN
U24297TG2014PTC095025
- Company No.
095025
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jul 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Seutic Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Valivarthi  | Director | 23-Jul-2014 | Current |
| Padma Valivarthi | Director | 23-Jul-2014 | Current |
Financial Performance of Seutic Pharma.
Seutic Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 83.76% increase. The company also saw a substantial improvement in profitability, with a 133.89% increase in profit. The company's net worth Soared by an impressive increase of 24.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Seutic Pharma?
In 2021, Seutic Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Seutic Labs Private LimitedActive 8 years 10 monthsVenkata Valivarthi and Padma Valivarthi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Sep 2022 | ₹7.26 M | Open |
Others Creation Date: 30 Dec 2021 | ₹1.00 Cr | Open |
Others Creation Date: 30 Sep 2021 | ₹28.18 Cr | Open |
How Many Employees Work at Seutic Pharma?
Seutic Pharma has a workforce of 58 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Seutic Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Seutic Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
